Dr. Roth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Palmetto Parkway
Hilton Head, SC 29928Phone+1 513-604-2360
Education & Training
- University of Cincinnati Medical Center/College of MedicineFellowship, Cardiovascular Disease, 1979 - 1980
- Christ HospitalResidency, Internal Medicine, 1976 - 1979
- University of Cincinnati College of MedicineClass of 1976
Certifications & Licensure
- OH State Medical License 1977 - 2026
- SC State Medical License 2016 - 2025
- KY State Medical License 2003 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FNLA) National Lipid Association, 2005-2020
- Fellow (FACC) American College of Cardiology, 1981-2020
Clinical Trials
- The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia Start of enrollment: 2006 May 01
- Diazoxide Choline in Hypertriglyceridemia Start of enrollment: 2008 Jun 01
- A Study of LY2623091 in Participants With High Blood Pressure Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trialEli M. Roth, John J.P. Kastelein, Christopher P. Cannon, Michel Farnier, James M. McKenney
Journal of Clinical Lipidology. 2020-07-25 - 5 citationsEfficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated StatinDirk Müller-Wieland, Daniel J. Rader, Patrick M. Moriarty, Jean Bergeron, Gisle Langslet
The Journal of Clinical Endocrinology and Metabolism. 2019-11-01 - 12 citationsRelationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.Jennifer G. Robinson, Michel Farnier, John J.P. Kastelein, Eli M. Roth, Marja-Riitta Taskinen
Journal of Clinical Lipidology. 2019-11-01
Press Mentions
- Get down with the Sickness: A Horror Fan’s Guide to Surviving the CoronavirusMarch 10th, 2020
- PCSK9 Antidrug Antibodies: Not a Class EffectMarch 18th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: